• Published on

    Case 7-Giant cell glioblastoma, WHO grade IV

    Picture

    32 y.o., female, multiple hyperdense lesions on the right parietal region. One representative section.Immunohistochemistry shows the malignant cells are positive for GFAP and negative for pan-cytokeratin and HMB-45.

    Educational notes:
    1. Section shows tumor tissue fragments composed of bizarre malignant cells with angulated hyperchromatic nuclei and abundant cytoplasm. Numerous multinucleated tumor giant cells are admixed. Mitoses are easily observed. The adjacent glial tissue is focally infiltrated by malignant
    cells. Immunohistochemistry shows the malignant cells are positive for GFAP and negative for pan-cytokeratin and HMB-45. Histological findings are consistent with giant cell glioblastoma, WHO grade IV. (Note: Without IDH evaluation, a diagnosis of glioblastoma, NOS, is more appropriate, vide infra)
    2. The 2016 World Health Organization Classification of Tumors of the Central Nervous System employs integrated phenotypic and genotypic parameters for tumor classification. Glioblastomas are classified into (1) glioblastoma, IDH-wildtype (about 90 %), which corresponds to the clinically defined primary or de novo glioblastoma in older patients; (2) glioblastoma, IDH-mutant (about 10%), which corresponds to secondary glioblastoma with a history of prior lower grade diffuse glioma in younger patients, and (3) glioblastoma, NOS, a diagnosis for those tumors that IDH
    evaluation cannot be performed.
    3. Along with gliosarcoma and epithelioid glioblastoma, giant cell glioblastoma is a variant under the umbrella of glioblastoma, IDH-wildtype. Histologically, it is characterized by bizarre, multinucleated giant cells and an occasionally abundant reticulin network. Palisading and large
    ischaemic necroses are observed. Atypical mitoses are frequent. Microvascular proliferation is not common. Giant cell glioblastoma has a somewhat better prognosis than ordinary glioblastoma.
    Reference:
    1. World Health Organization. (2016). WHO Classification of Tumours of the Central Nervous System Revised 4th Edition. David N. Louis, (Ed.). Internat. Agency for Research on Cancer.
  • Published on

    Sunway Medical Centre

    International Academy of Pathology — Malaysian Division

    10th IAPMD Scientific Meeting

    October 2, 2025

    10th IAPMD Scientific Meeting at Sunway Medical Centre

    We were proud to be the venue sponsor of the 10th Scientific Meeting of the International Academy of Pathology – Malaysian Division (IAPMD), held on 1–2 October 2025 at the SunMed Convention Centre.

    The meeting brought together pathologists and healthcare professionals for scientific exchange, professional networking and continued learning.

    The event provided an excellent opportunity for members of the pathology community to share knowledge and strengthen professional connections.
    ```
  • Published on

    Case 6 : Mycosis fungoides with large cell transformation

    Picture
    ​HISTORY: 68/Male/Presented with patches and plaques at trunk, UL, LL with tumour-like lesion at thigh

    EDUCATIONAL NOTES:


    1) Section from the left thigh punch biopsy shows diffuse dermal infiltration by large neoplastic lymphoid cells arranged in solid sheets. The cells display moderate to markedly pleomorphic vesicular nuclei with prominent multiple nucleoli. The cytoplasm is eosinophilic and ample in amount. Mitotic figures are frequently seen.
    Occasional histiocytes and small reactive lymphocytes are appreciated in the background.
    The overlying epidermis shows marked acanthosis and parakeratosis with prominent lymphocyte epidermotropism and Pautrier microabscesses. No angio-invasion or angio-destruction is seen.
    2) Immunohistochemistry study shows the neoplastic lymphoid cells are immunoreactive (+) for CD2, CD3 and CD5, with aberrant loss in CD7 and CD8. CD4 is positive (+) in a significant number of cells. CD30, ALK-1 and CD20 are negative (-). The proliferative index as estimated by Ki67 is high (>90%).
    3) The evolution of patches and plaques followed by tumoral stage further supports the diagnosis of large cell transformation Mycosis fungoides (MF).
    Transformation MF is defined by: -
    1. Presence of 25% blastic cells (large cells, 4x reactive lymphocytes).
    2. Discrete tumour cell nodule. CD30 positive cells are only seen in ~ 30-50% of cases and is not required in making the diagnosis.
    4) MF is defined as epidermotropic PCTCL of small to medium-sized T lymphocytes with cerebriform nuclei. The term should only be used for classical cases (i.e evolution of patches, plaques, and tumours + variants with a similar clinical course).
    5) MF is the most common subtype of CTCL, accounting for approximately half of all cutaneous lymphomas. Patients with MF most often experience a protracted clinical course in which disease patches, plaques, and tumors develop over several years or even decades.
    6) Some patients, however, undergo a process of large-cell transformation (LCT) which may be characterized by a more aggressive disease course and shortened survival. Early recognition of the clinical clues associated with LCT allows the dermatologist to diagnose this entity earlier and offer patients more aggressive treatment regimens.
    7) The prognosis of LCT is reportedly worse than classic MF, and the median survival from diagnosis of LCT has been cited as 37 months for patients with LCT compared with 163 months for those with more classic MF without LCT.
    Other studies have reported median survivals as low as 1 month.
    REFERENCES:
    • Mc Kee’s Pathology of The Skin
    • E. Olsen et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood (2007)
    • B. Vergier et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood (2000)
    • WHO Classification of Skin Tumours. WHO Classification of Tumours, 4th Edition, Volume 11. Edited by Elder DE, Massi D, Scolyer RA, Willemze R
  • Published on

    CPATH

    International Academy of Pathology — Malaysian Division

    IAPMD Achievement

    Lifetime Achievement Award
    August 31, 2025

    Congratulations to Prof Emerita Dr Nor Hayati Othman

    Our sincere congratulations to our President, Prof Emerita Dr Nor Hayati Othman, for being the recipient of the College of Pathologists, Academy of Medicine Malaysia Lifetime Achievement Award.

    The award recognises her outstanding contribution to pathology and the medical profession, as well as her dedication to the advancement of pathology in Malaysia.

    A remarkable achievement and a proud moment for IAPMD.
    ```
  • Published on

    Case 5: Granular cell tumour

    Granular cell tumors were described as early as 1926 by the Russian pathologist Abrikossoff. They were initially coined granular cell myoblastomas, as they were believed to be of muscular origin. With the advent of immunohistochemical stains and electron microscopy, they are now believed to be Schwannian derivation. Notably, a subset of S100-negative “non-neural” granular cell tumors have been identified which may not derive from neural tissue.
    These rare tumors are most commonly reported in the skin, oral cavity, digestive tract, and subcutaneous tissue. However, they can occur anywhere in the body, including breast, bladder, nervous system, respiratory and genitourinary tracts. All age groups and genders can be affected, but it is classically found in women in their 4th to 6th decades of life.Granular cell tumors typically present as solitary, painless nodules less than 3-4 cm large and may be found incidentally.
    The vast majority behave indolently. Based on histologic criteria or the presence of metastasis, however, 1% to 2% of these lesions can be malignant, with poor prognosis and few curative options beyond surgical excision.
    Picture

    17 years old girl with no known medical illness. C/o swelling over left middle finger for past 1 year. Gradually increasing in size. Pain when pressured eg. picking up object. No limited range of movement. Clinical dx: Left middle finger giant cell tumour (volar)

    In granular cell tumour, sections show broad fascicles of tumour cells arranged in nests or sheets infiltrating the dermis and dermal structures. The tumour cells are large in size, with small, uniform, eosinophilic granules filling the cytoplasm, and small, round-to-oval nuclei. Mitoses are rare.

    Picture
    'Pustulo-ovoid bodies of Milian' may be present. These are large granules surrounded by a clear halo.
    Picture
    Sections show broad fascicles of tumour cells arranged in nests or sheets infiltrating the dermis and dermal structures. 

    Sometimes, the overlying epidermis may become markedly hyperplastic and mimic a squamous cell carcinoma. This is thought to be a reactive phenomenon.
    Malignant forms of granular cell tumour are extremely rare but reported. Frank anaplasia, increased mitotic activity and tumour necrosis are worrisome features.

    Picture
    Special studies for granular cell tumour

    ​S-100 protein is positive. PAS highlights granules after diastase digestion. Other positive stains may include SOX10 , inhibin , neuron specific enolase, CD68, and CD56.


    Differential diagnosis of granular cell tumour pathology :

    Rhabdomyoma — These may be similar to granular cell tumour. Rhabdomyomas are positive with desmin and myoglobin.
    S-100 immunohistochemical positivity in rhabdomyoma: An underestimated potential diagnostic pitfall in routine practice



    Gingival granular cell tumour of newborn ( Congenital epulis of newborn)— These are morphologically similar to granular cell tumour but arise in a distinct clinical setting. S100 is negative.

    Other tumours with granular cells – Granular cell change has been described in many other tumours (including dermatofibroma, fibrous papule, AFX and primitive polypoid granular cell tumour - See below). S100 positivity is generally a useful diagnostic aid.
    Picture
    Primitive Polypoid Granular-Cell Tumor
    Tumor in the superficial and mid dermis, surrounded by an epithelial collarette. 
    Cells with a polygonal morphology, abundant granular eosinophilic cytoplasm, and large vesicular nuclei. The cells are arranged in an interlinked fascicular pattern.
    In contrast to conventional granular cell tumor (Abrikossoff tumor), primitive polypoid granular cell tumor was first identified by LeBoit et al.1 in 1991 and subsequently endorsed by Chaudhry and Calonje2 as a dermal tumor of granular cells of non-neural origin. The tumor has a polypoid morphology and presents numerous mitoses, cytologic atypia, and a primitive immunophenotype. 
  • Published on

    Case 4 :  Small cell carcinoma of hypercalcemic type

    Picture

    16 y.o, female, abdominal mass, left ovary, high serum calcium. One representative section.

    Educational notes:

    1. The left ovarian mass is composed of diffuse growth of small cells showing irregular round to oval nuclei with small nucleoli. The cytoplasm is scanty. Mitoses are scattered. At focal areas, cystic spaces containing light eosinophilic secretion is observed.

    These 
    small cells are focally immunoreactive towards CKMNF116, CD10, calretinin, EMA, and synaptophysin.

    They are diffusely positive for WT1.

    ​They are negative for chromogranin 
    and inhibin.

    2. Morphologically, the ovarian mass is composed of undifferentiated small cells with a high mitotic count. Small cell carcinoma of hypercalcemic type of the ovary (SCCHT) and granulosa cell tumor of the juvenile type (JGCT) are the main differential diagnoses in this young female patient.

    3. In JGCT, follicle-like spaces containing eosinophilic or basophilic secretions are more numerous. JGCT may have fibrous septa and fibrothecomatous component. In contrast, SCCHT has focal follicle-like spaces with scanty stroma. The most useful immunohistochemical marker to differentiate between these two is inhibin whereby it is positive in JGCT but negative in SCCHT.

    4. Clinically, SCCHT is usually associated with hypercalcemia whereas JGCT with estrogenic manifestations.

    5. JGCT mostly presents at stage I with excellent prognosis whereas SCCHT is a highly aggressive tumor with a poor prognosis (almost all patients with a stage higher than stage Ia died of disease)

    Reference
    1. Soslow, R. A., & Tornos, C. (Eds.). (2011). Diagnostic pathology of ovarian tumors. Springer Science &
    Business Media.
    2. Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014). WHO classification of tumours of
    female reproductive organs. Lyon: International Agency for Research on Cancer.